Lundbeck to test Vyepti in direct comparison with competitors

In a new phase IV real-world study, Lundbeck will test how well migraine infusion Vyepti does compared to other therapies of the same class.
Photo: Thomas Borberg/Politiken/Ritzau Scanpix
Photo: Thomas Borberg/Politiken/Ritzau Scanpix
by MIKKEL AABENHUS HEMMINGSEN & CHRISTIAN BUNDGAARD, translated by daniel pedersen

200 people in the US will help shed light on how well the newest generation of migraine therapies perform in a direct comparison of their preventive effects on migraine episodes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading